Infectious disease

Preparing for the next pandemic

As a leading developer of molecular technologies, our aim is to make reliable, efficient, and rapid testing solutions available to as many people as possible, around the globe. The COVID pandemic has demonstrated that speed is critical in responding to a novel pathogen, and our strategies focus on just that – getting more tests to those that need them quickly.

Get the right diagnosis the first time

We understand how challenging it can be to quickly and accurately diagnose infectious diseases. When a patient is ill and time is of the essence, how do you make sure you test for the right pathogen the first time?

That's exactly when syndromic testing really shines. Unlike traditional diagnostic methods, like bacterial culture and microscopy, syndromic testing uses multiplex PCR to test for several pathogens at once – and it only takes around an hour.

Building a world free of TB

Tuberculosis (TB) is an airborne, highly contagious, infectious disease caused by Mycobacterium tuberculosis (MTB). Most frequently, TB affects the lungs, however, it can also cause disease in any part of the body, such as the lymph nodes, bones, brain, organs and eyes.

TB is a serious disease that claims millions of lives each year worldwide, and it can significantly impact healthcare systems and economies. TB testing is important because it can lead to early treatment and better health outcomes. By diagnosing and treating TB infection early, we can help prevent the spread of the disease and reduce its impact on the community.

Improving care for transplant recipients

Immunocompromised transplant patients are highly susceptible to post-op infections. What can you do when viral load assays don't give you a complete diagnostic picture of your patient's immune response?

QuantiFERON transplant assays provide a complementary approach – helping you assess the risk of infection and guide your patient management.